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The granulocyte-macrophage colony-stimulating factor (GM-CSF) is a hematopoietic
cytokine able to regulate a variety of cell functions including differentiation of
macrophages and granulocytes, dendritic cell development and the maintenance of
homeostasis. It binds specifically to its receptor, which is composed of a cytokine-
specific a-chain (GM-CSF receptor a-chain, GMRa) and a b-chain shared with the
receptorsfor interleukin-3andinterleukin-5.Inthisreport,wepresentacomprehensive
study of GMRa in the mouse. We have found that the mouse GMRa is polymorphic and
alternatively spliced. In the absence of specific antibodies, we generated a novel
chimeric protein containing the Fc fragment of human IgG1 coupled to mouse GM-CSF,
which was able to specifically bind to GMRa and induce proliferation of
GMRa-transduced Ba/F3 cells. We used this reagent to perform the first detailed
FACS study of the surface expression of mouse GMRa by leucocytes. Highest expression
was found on monocytes and granulocytes, and variable expression on tissue
macrophages. The GM-CSF receptor in mice is specifically expressed by myeloid cells
and is useful for the detection of novel uncharacterised myeloid populations. The ability
to detect GM-CSF receptor expression in experimental studies should greatly facilitate
the analysis of its role in immune pathologies.
Introduction
The granulocyte-macrophage colony-stimulating factor
(GM-CSF) was first isolated from mouse lung cell-
conditioned media as a small glycoprotein (24–33 kDa)
able to generate both macrophage and granulocyte
colonies from mouse bone marrow precursor cells [1].
However, a variety of studies have shown other relevant
functions including its capacity to enhance host defense
mechanisms against bacterial and fungal infection [1],
itscontributiontodendriticcelldevelopment[2],andits
involvement in the catabolism of pulmonary surfactant
to maintain homeostasis in the alveoli of the lung [3].
GM-CSF can modulate effector functions not only on
myeloid cells but also on other cell types expressing the
GM-CSF receptor including type II alveolar epithelial
cells [4], CD34
+ progenitor cells [5], uterine cells [6],
vascular endothelial cells [7, 8] and fibroblasts [9].
GM-CSF binds specifically to its receptor, which is
composed of a cytokine-specific a-chain (GM-CSF
receptor a chain, GMRa) and b-chain (bc), which is
shared with the receptors for interleukin (IL)-3 and IL-5
[10].ItassociateswithGMRawithlowaffinity andrapid
dissociation kinetics, but the formation of the
ab heterodimeric complex mediates a stable interaction
with high affinity and slow dissociation kinetics. Besides
enhancing cytokine binding, the bc plays a key role in
signal transduction, which can also be modulated by
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homologous bc, AIC2A and AIC2B. IL-3 can induce the
formation of the ab complex using either AIC2A or
AIC2B, but only AIC2B is able to create the ab complex
for GM-CSF and IL-5 [13, 14].
Molecular cloning of the mouse GMRa cDNA
revealed a single transmembrane polypeptide of
387 amino acids with relatively low homology to its
human counterpart (less than 35%). It is a type I
membrane protein subdivided into three regions: an
extracellular domain, a transmembrane region, and a
cytoplasmic domain. The extracellular domain shares
conserved structural features of the cytokine receptor
superfamily containing three fibronectin type III
(FN-III)-like domains, four cysteine residues involved
in heterodimerization of the receptor, and an imperfect
WSXWS box (WGEWS), which is required for protein
folding and cell surface receptor binding [11, 15]. The
cytoplasmic domain is short and characterised by the
presence of a highly conserved proline-rich domain
(PPXP), which is adjacent to the plasma membrane and
involved in signal transduction (reviewed in [10]).
Several studies on the human GMRa have demon-
strated that as consequence of alternative splicing or
metalloproteinase activity, GMRa loses its tramsmem-
brane domain resulting in a soluble isoform, which is
able to antagonise GM-CSF binding and function
[16–19]. However, alternatively spliced isoforms of
the murine receptor have not been reported [15].
Inspiteof theobviousimportanceofGM-CSFandthe
wide use of mice in immunological studies there are no
useful reagents for the detection of the mouse GMRa or
extensive studies of its expression and function. In this
report, we present a comprehensive study of GMRa in
the mouse. We have found that the mouse GMRa is
polymorphic and alternatively spliced. Due to the
restricted availability of specific antibodies against the
extracellular domain of GMRa, we coupled the mouse
GM-CSF to the Fc fragment derived from human IgG
(GM-Fc) to characterise surface expression of the mouse
GMRa on distinct leucocyte populations. GM-Fc is able
tobindandactivatethereceptor,andthereby,providesa
novel way to examine the regulation and expression of
GMRa during steady state and immunological chal-
lenge.
Results
The mouse GM-CSF receptor is alternatively
spliced and polymorphic
Early studies on the characterisation of the murine
GMRafailed todetectalternativelyspliced isoforms [15]
butasolublereceptorabletoblockGM-CSFfunctionhas
been identified for the human counterpart [17]. Using
cDNA from bone marrow cells, we identified full-length
transcripts with open reading frame of 1167 bp
(388 amino acids) for Balb/c and C57BL/6 mice, which
are polymorphic at amino acid residue 227 (Asp and
Gly, respectively) (Fig.1A, B). We also found alternative
splice forms in C57BL/6: a deletion isoform
(~223–247), which lacks part of the FN-III domain,
and a truncated isoform that would be predicted to be
soluble due to the absence of a transmembrane domain
(Fig. 1). These sequences have been submitted to
GenBank (accession numbers: EF114317 and
EF114318).
Figure 1. Characterisation of GMRa in the mouse model. (A)
Schematic representation of the 11 exons coding for GMRa.
The recently published sequence (Ensembl release 40) corre-
sponds to the full-length sequence of C57BL/6 mice whereas
Balb/c mice display a polymorphic change in exon 6. We
observedtwoadditional spliceforms,onewithasmalldeletion
and a truncated form, the changes in which are shown
schematically. Black arrows indicate coding exons while grey
arrows indicate non-coding sequence. (B) Schematic repre-
sentation of the three predicted isoforms of the mouse GMRa.
Thefull-lengthisoformiscomposedofashortcytoplasmictail,
a transmembrane region and an extracellular region, which
contains an FN-III domain where there is a polymorphic
change at residue 227* (Aspfor Balb/cand Glyfor C57BL/6).The
deletion transcript results in an in-frame deletion in the FN-III
domain, but retains a transmembrane domain. The truncated
isoform has a premature stop codon.
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csf2ra, has only recently been completed (mouse
genome sequence Ensembl release 40). The transcripts
we identified are shown schematically alongside this
genomic sequence in Fig. 1A. The deletion isoform
appears to be created by skipping of the splice acceptor
ofexon 6 and aberrant splicing intothe coding sequence
of exon 6. Similarly the truncation isoform is the result
of inclusion of the fifth intron into the final transcript
resulting in a premature stop codon (Fig. 1A).
Functional analysis of polymorphic variants of
the mouse GM-CSF receptor
We expressed full-length GMRa from both Balb/c and
C57BL/6 mice in Ba/F3 cells, which constitutively
express both AIC2A and AIC2B bc [14], permitting
the generation of a functional ab receptor, which should
respond to GM-CSF. We cultured Ba/F3 cells (trans-
duced with empty vector or GMRa-encoding vectors) in
the presence of IL-3 or GM-CSF, and assessed cell
proliferation daily by determining the percentage of
reduction of Alamarblue, an oxidation-reduction in-
dicator that changes color in response to metabolic
activity [20].
We found that empty vector-transduced control cells
(Ba/F3:pFB), like untransduced Ba/F3 cells (data not
shown), proliferated only in the presence of IL-3, but
GMRa-transduced Ba/F3 cells (Ba/F3:GMRa) could
proliferate in either IL-3 or GM-CSF (Fig. 2A). Using
these conditions, we were able to detect significant
proliferation of Ba/F3:GMRa after 5 days in culture
with a concentration of GM-CSFas low as 0.032 ng/mL.
Since we did not have a reagent to monitor expression of
thepolymorphic forms ofGMRa,wecalculatedaratio of
proliferation to compare the functional activity of the
polymorphic variants of GMRa in response to both GM-
CSF and IL-3 (Fig. 2B). We found a similar proliferation
ratio for both polymorphic forms of GMRa, indicating
that the polymorphism does not affect responsiveness of
the cell to GM-CSF.
A novel GM-CSF chimeric protein and assessment
of its functionality
The lack of antibodies against the extracellular domain
of mouse GMRa has greatly restricted the study of this
receptor. In order to circumvent this limitation, we
designedachimericproteinfusingthemouseGM-CSFto
a mutated Fc region of human IgG1 (GM-Fc)
(Fig. 3A, B), which contains point mutations to avoid
complement activation and Fc receptor binding [21]. To
evaluate the functionality of GM-Fc, we first determined
its capacity to recognise Ba/F3 cells expressing GMRa
(Fig. 3C). GM-Fc was able to bind the two polymorphic
variants of GMRa (Balb/c and C57BL/6) while binding
to cells transduced with empty vector was not detected.
We next cultured Ba/F3 cells (Ba/F3:pFB and Ba/
F3:GMRa) in presence of either GM-CSF or GM-Fc and
assessed cell proliferation as indicated above (Fig. 4A).
Similarly to GM-CSF, GM-Fc was effective at inducing
proliferation of Ba/F3:GMRa (Fig. 4B). To determine
whether the polymorphism between C57BL/6 and Balb/
cmiceaffectedbindingof thecytokine,wemeasuredthe
binding of the recombinant protein to both transduced
cell lines. Therewas no marked differencein the binding
between the Balb/c (KD = 15.6 nM, 95%-confidence
interval: 10.9–20.3) and C57BL/6 (KD = 19.6 nM,
95%-confidence interval: 15.6–23.6) forms of the
receptor.
Figure 2. Functionality of polymorphic forms of GMRa. (A) Full-
length GMRa from Balb/c and C57BL/6 mice were retrovirally
transduced into Ba/F3 cells. Ba/F3 cells transduced with empty
vectororGMRa-encodingvectorswereculturedinthepresence
of4 ng/mLofGM-CSF(filledcircles)orIL-3(opencircles)forthe
indicated number of days (left panels) or in the indicated
concentrations of cytokine for 8 days (right panels). Cell
proliferation was measured by determining the percentage
of reduction of Alamarblue. (B) The ratio of proliferation in
response to GM-CSF and IL-3 was calculated to compare the
polymorphic variants; filled squares: Ba/F3:pFB; open circles:
Ba/F3:GMRa (Balb/c); filled circles: Ba/F3:GMRa (C57BL/6).
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of GMRa
We next assessed the functional activity of the
alternative splice forms of GMRa. Ba/F3 cells, stably
transduced with the deletion and truncation isoforms of
GMRa,wereunabletobind GM-Fc (Fig.5A).Weverified
this by culturing Ba/F3 cells expressing either the
deletionor thetruncation GMRaisoforminthe presence
of IL-3, GM-CSF or GM-Fc. Only those cells expressing
thefull-lengthGMRaproliferatedinthepresenceofGM-
CSF or GM-Fc. The cells expressing the deletion or
truncation isoforms were only able to proliferate in the
presence of IL-3 (Fig. 5B).
Detection of GMRa on the surface of primary
leukocytes
Cell surface expression of GMRa has been broadly
studied in human cells [22], but little is known about its
expressioninthemousemodel.WeusedGM-Fctodetect
GMRa in different cell populations in blood, bone
marrow and spleen. A detailed analysis of GMRa
expression by the cell populations in peripheral blood
is presented in Fig. 6. All populations of granulocytes
(Gr-1
highSSC
highF4/80
– neutrophils, Gr-1
lowSSC
v.highF4/
80
+ eosinophils and CD49b
+IgE
+SSC
high basophils) as
well as Gr-1
+ and Gr-1
– monocytes (SSC
lowF4/
80
+CD11b
+) expressed similar levels of GMRa, with
monocytes expressing the highest levels (Fig. 6A, B),
whileTcells(CD3
+),NKcells(CD3
–CD49b
+)andBcells
(CD19
+) lacked GMRa expression (Fig. 6C). The
control-Fc chimeric protein (CR
W117A-Fc) was unable
to bind either myeloid or lymphoid cells confirming the
specificity of GM-Fc binding. The expression data from
spleen and bone marrow are compared tothose of blood
and summarised in Table 1. Consistent with the
expression pattern reported for the human homologue,
we found that myeloid cells but not lymphoid cells
expressed GMRa (Fig. 6 and Table 1).
Expression of GMRa on macrophages
Since GM-CSF plays an important role in the production
and function of macrophages, we analysed the expres-
sion of GMRa on inflammatory-elicited peritoneal
macrophages and on alveolar macrophages. Macro-
Figure 4. Effect of GM-Fc on Ba/F3 cells expressing full-length
GMRa isoforms. (A) Ba/F3:pFB (filled squares), Ba/F3:GMRa
(Balb/c; open circles), and Ba/F3:GMRa (C57BL/6; filled circles)
were cultured in the presence of either GM-CSF or GM-Fc and
cell proliferation was determined using Alamarblue as in-
dicated previously. (B) Expressing percentage Alamarblue
reduction obtained when GM-Fc or GM-CSF was used as a
growth factor as a ratio shows that both agents have a similar
capacity to support proliferation of Ba/F3:GMRa cells. (C) The
ability of the C57BL/6 and Balb/c isoforms of GMRa to bind to
the cytokine was assessed using GM-Fc and analysed by non-
linear regression. Data shown represent pooled data from two
independent experiments, and error bars shown the SEM.
Figure 3. Generation and characterisation of a GM-CSF-Fc
fusion protein. (A) Graphic representation of GM-Fc, a chimeric
protein generated by fusing the mouse GM-CSFto a mutated Fc
region of human IgG1. (B) GM-Fc purity was assessed by
Coomassie blue staining of protein resolved under both
reducing (R) and non-reducing (NR) conditions by 10% SDS-
PAGE.(C)ThebindingcapacityofGM-Fc(greyline)toBa/F3cells
expressing GMRa from Balb/c or C57BL/6 mice was determined
byFACSasindicatedpreviouslyandcomparedtothecontrol-Fc
protein (black line).
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Ba/F3 cells expressing the deletion and truncation GMRa from C57BL/6 mice was determined by FACS as indicated previously. (B)
Ba/F3:pFB, Ba/F3:GMRa (C57BL/6), the deletion and truncation isoforms (C57BL/6) were cultured in the presence of either GM-CSF,
GM-Fc, or IL-3-conditioned medium or in the absence of cytokine. Cell proliferation was determined using Alamarblue as
indicated previously.
Figure 6. Detection of GMRa on the surface of blood leukocytes. Cell surface expression of mouse GMRa in different blood cell
populationswas determined by FACSusing GM-Fcorcontrol-Fc. (A) Granulocytesweregated by their SSC
highFSC
int–high phenotype
(left panel 1), and subdivided into neutrophils (Neu, Gr-1
highSSC
high; left panel 2), eosinophils (Eos, Gr-1
lowSSC
v.high; left panel 2)
and basophils (Bas, CD49b
+IgE
+; left panel 3). Binding of control-Fc (middle panels) and GM-Fc (right panels) was then assessed on
the three populations as indicated. GM-Fc bound to all three granulocyte populations (B) Monocytes (Mo) were identified by their
F4/80
+CD11b
+ phenotype (left panel) after gating on SSC
low cells (not shown). The monocytes were further divided by their
expression of Gr-1 and assessed for binding of control-Fc (middle panel) or GM-Fc (right panel). GM-Fc bound well to both major
monocyte subsets. (C) GMRa expression was also determined on lymphoid cells. T cells (top panels, gated on CD3
+), NK cells
(middle panels, gated on CD3
–CD49b
+) and B cells (bottom panels, gated on CD19
+) were assessed for binding of GM-Fc (grey lines)
and control-Fc (black line). No specific binding of GM-Fc was detected on the lymphocyte populations.
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thioglycollate broth or biogel (Fig. 7A) exhibited high
levels of GMRa, as did alveolar macrophages (Fig. 7A).
Injection of thioglycollate broth or biogel recruited
neutrophils and eosinophils. These cells also expressed
GMRa but the levels of receptor were lower than in the
inflammatory macrophages (data not shown).
To determine changes in the expression of GMRa
following stimulation, we treated RAW264.7 cells (a
mouse macrophage-like cell line expressing high levels
of GMRa on their cell surface) with a range of
inflammatory insults and assessed binding of GM-Fc.
We found that RAW264.7 cells selectively up-regulated
GMRa surface expression in response to avarietyof Toll-
like receptor agonists, including Pam3CSK4, flagellin,
lipopolysaccharide (LPS) and zymosan, but not to
poly(I:C) (Fig. 7B).
Expression of GMRa as a marker of myeloid cells
The restriction of GMRa to cells of the myeloid, but not
lymphoid, lineage indicated that GMRa may be a useful
marker of myeloid cells in the mouse. The peritoneal
cavity contains a variety of immune cells, which have
traditionally been considered as the first line of defence
against invasion of micro-organisms in the peritoneum
[23]. We used GM-Fc to identify GMRa-expressing cells
in the resting peritoneal cavity, and the positive
population was further analysed by expression of the
additional myeloid markers F4/80 and CD11b. The
peritoneal GMRa
– cells corresponded predominantly to
lymphocytes, mainly B cells (data not shown).
We were able to clearly differentiate three distinct
populations (Fig. 7C). The most common population
representing about 30–40% of peritoneal cells had the
classic phenotype of resident peritoneal macrophages
(CD11b
highF4/80
high, population 1 in Fig. 7C). A sparse
population, which expressed moderate levels of both
CD11b and F4/80, had high SSC and shared additional
markers with eosinophils (Fig. 7C and data not shown).
Most interesting was the identification of an apparently
novel cell type, which represented between 1 and 5% of
the peritoneal cells depending on mouse strain and had
a CD11b
high, but F4/80
low phenotype. We subsequently
purified and began the functional characterisation of
these cells. They express high levels of MHC class II and
can present antigen to ovalbumin-specific CD4
+ T cells
from naive DO11.10 mice indicative of a dendritic cell-
like phenotype (Dioszeghy et al., manuscript in
preparation).
Discussion
Thestructureandfunctionof thehumanGMRahasbeen
broadly investigated, and several studies using mice
lacking either GM-CSF [24, 25] or the bc of its receptor
[26, 27], as well as administration of GM-CSF [28–30]
or neutralising antibodies against the cytokine [31, 32]
have been used in models of disease. However,
fundamental knowledge about the nature of expression
and function of the mouse GMRa is lacking.
In this study, we cloned GMRa-coding sequences
from Balb/c and C57BL/6 mice. We found that mouse
GMRa is polymorphic at amino acid residue 227 (Asp
Table 1. Summary of the expression of GMRa by mouse leukocytes
Tissue
a)
Cell type Phenotype Blood Spleen Bone marrow Peritoneal cavity
Monocytes
b) SSC
lowCD11b
+F4/80
+ +++ N D
Macrophages
c) F4/80
high ND + ND +
Neutrophils SSC
highCD11b
+Gr-1
high +++ +
Eosinophils SSC
v.highCD11b
+Gr-1
low +++ +
Basophils SSC
medCD49b
+IgE
+ +N D N D N D
Dendritic cells
d) CD11c
high ND + ND +
T cells CD3
+ ––– N D
B cells CD19
+ ––– –
NK cells CD3
–CD49b
+ ––– N D
a) + denotes GMRa expression; – denotes absence of detectable GMRa expression; ND denotes not detectable or not determined.
b) Refers collectively to both Gr-1
+ and Gr-1
– monocytes.
c) Splenic macrophages are identified by autofluorescence and F4/80 expression, whereas peritoneal macrophages also express
high levels of CD11b.
d) Dendritic cell-like cells in the peritoneal cavity express relatively low levels of CD11c.
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as amplifying full-length clones, we identified two
alternatively spliced isoforms that have not been
previously described. These alternatively spliced iso-
forms were expressed in bone marrow cells, where the
predominant expression of GMRa is by neutrophils and
monocytes (Table 1). We retrovirally transduced the
IL-3-dependent AIC2A/AIC2B-expressing Ba/F3 cell
line with the full-length GMRa clones from Balb/c or
C57BL/6 mice. The Ba/F3:GMRa cells were able to
proliferate in response to GM-CSF, unlike the control
vector-transduced cells, and comparative analysis of the
responses to cell lines to IL-3 and GM-CSF indicated that
the polymorphism did not significantly affect receptor
function. Apart from the polymorphic residue men-
tioned above, our sequences were identical to the
published cDNA [15].
Since there are no commercial reagents for the
detection of mouse GMRa at the cell surface, we
designed a chimeric protein (GM-Fc) which had mouse
GM-CSF fused to the Fc domain of human IgG1 (Fig. 3).
GM-Fc bound specifically to GMRa-transduced Ba/F3,
but not control transduced cells, confirming its speci-
ficity as a receptor-detecting reagent. However, GM-Fc
was not suitable for immunohistochemical analysis of
the expression of GMRa in fixed tissue sections, most
likely because of the need for heterodimeric receptor for
high-affinitybinding.GM-Fcwasalsoabletosupportthe
proliferation of the GMRa-transduced Ba/F3 cells,
indicating that the reagent functioned in a comparable
way to the natural cytokine making possible its
implementation in functional studies in vitro and in
vivo. GM-Fc was thus a specific and sensitive immuno-
logical tool to study the expression of the murine GMRa
on a variety of cell types.
Figure 7. Expression of GMRa by macrophages and characterisation of myeloid cells. (A) Inflammatory peritoneal macrophages
were elicited by intraperitoneal administration of thioglycollate broth (top panels) or biogel (middle panels) for 4 days. GMRa
expression was analysed by FACS along with the macrophages identified by F4/80 and CD11b profiles (gated regions). Alveolar
macrophageswereisolatedfromlunglavageandgatedinaccordancewiththeexpressionofF4/80andCD11c(bottompanels).GM-
Fc (right panels, grey lines), when compared to control-Fc (right panels, black lines), bound specifically and at high levels to the
macrophage populations. (B) RAW264.7 cells were stimulated with 100 ng/mL poly(I:C), Pam3CSK4, flagellin or LPS or
5 10
6 particles/well of zymosan. After 24 h, binding of GM-Fc was assessed by FACS. Data represent the results of four
independent experiments and error bars are the SD. Data were analysed by repeated measures one-way ANOVA with Dunnet's
post test; *p<0.05, **p<0.01. (C) We used GM-Fc to identify GMRa-expressing cells in the resting peritoneal cavity (upper panels).
Gating on GMRa
+ cells identifiedthreepopulations of myeloid cells, whichexpressed distinctlevels of the myeloid markersCD11b
and F4/80 (populations 1–3, upper right panel). The physical FSC/SCC profiles of three populations are shown in the lower panels.
Population 1exhibitstheclassicF4/80
highCD11b
highphenotypeofresidentperitonealmacrophages.ThesecondF4/80
lowCD11b
high
population also expressed MHC class II and exhibited dendritic cell-like characteristics (Dioszeghy et al., manuscript in
preparation) and the third rarer population shared the phenotype of eosinophils.
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transmembrane region (truncated isoform, Fig. 1),
which by analogy to the human receptor isoforms could
be secreted into the extracellular environment as a
soluble receptor capable of antagonizing receptor
functions [16, 17]. Consistent with this we were unable
to detect this isoform on the surface of transduced cells
with GM-Fc (Fig. 5A). The second isoform contained a
deletion (~223–247) within the FN-III domain, but had
an intact transmembrane domain and would be
predicted to be expressed at the cell surface (Fig. 1).
We were unable to detect GM-Fc binding on cells
transduced to express this isoform, suggesting that it
was incapable of cytokine binding (Fig. 5A). The
biological relevance of these isoforms remains to be
established but they could be significant in the
regulation of GMRa expression and in the study of
diseases associated with deficiency of GM-CSF:GM-CSF
receptor, such as pulmonary alveolar proteinosis [33].
Wehaveused GM-Fc for the first sensitiveassessment
of the surface expression of GMRa on primary
leucocytes derived from different mouse tissues. Simi-
larly to human cells [34], macrophages [alveolar and
peritoneal, both resident and inflammatory (thiogly-
collate- or biogel-elicited)], were the highest GMRa-
expressing cells followed by both Gr-1
+ and Gr-1
–
monocytes (from blood, spleen and bone marrow).
Neutrophils and eosinophils (from blood, spleen, bone
marrow and peritoneal lavage) as well as circulating
basophils expressed reasonable levels of GMRa but less
than those expressed by macrophages or dendritic cells.
Lymphoid cells (B cells, T cells and NK cells) derived
from blood, spleen and bone marrow did not express
GMRa. In the same way, human lymphocytes (B cells,
T cells and NK cells) do not express GMRa but its
presence has been demonstrated in some malignancies
like the hairy-cell leukaemia, breast and lung
carcinomas as well as on several hemopoietic cell lines
[35–37]. These data are also consistent with studies on
hematopoietic commitment and differentiation, which
have revealed that GMRa expression contributes to
the development of myeloid cells while its
expression impacts negatively on the lymphoid lineage
[38, 39].
We were unable to detect expression on non-
hemopoietic cell lines such as b.END-3, NIH3T3 and,
perhaps more interestingly given the role of GM-CSF in
the lung homeostasis, LA-4 respiratory epithelial cells
(data not shown). We extended these studies by
applying GM-Fc to the study of the macrophage
inflammatory response by determining changes in the
surface expression of GMRa in response to microbial
stimuli. The Toll-like receptor agonists Pam3CSK4,
flagellin, zymosan and LPS all induced an up-regulation
of GMRasurface expression, validating the use of GM-Fc
as a sensitive way to monitor the regulation of GMRa
expression by immune cells.
We were interested in the resident cells dwelling in
the peritoneal cavity, which are thought to be essential
in the local defensive response against infection [23].
The peritoneal cavity has been extensively exploited to
study inflammation but the resident myeloid cells have
not been well characterised. We defined three popula-
tions of GMRa-expressing cells in the peritoneal cavity
by their CD11b and F4/80 profiles (Fig. 7C). The major
population, representing 30–40% of the normal perito-
neal cells, had the classic phenotype of peritoneal
macrophages [40]. We also identified a second popula-
tion (CD11b
highF4/80
low), not previously described,
which after further functional analysis appears to
comprise dendritic-like cells, as determined by the
expression of MHC class II and ability to present antigen
to naive T cells (Dioszeghy et al., manuscript in
preparation). Several studies have suggested the pre-
sence of dendritic cells in the peritoneal cavity but they
have demonstrated a capacity to demonstrate antigen
only after in vitro differentiation [30, 41, 42]. The third
and rarest population shared an antigen phenotype with
eosinophils (data not shown) [43].
Taken together, this characterisation of the mouse
GMRa as well as its expression on leukocytes from
different tissues provides fundamental information that
can be applied to many immunological studies. The
receptor is polymorphic and importantly alternatively
spliced, indicating that the regulation of its function in
mousemodelsofdiseasemaybeascomplexasitshuman
counterpart. In the absence of antibodies, GM-Fc
provides a sensitive and specific tool for the study of
murine GMRa and its regulation during immunological
challenge.
Materials and methods
Mice and reagents
Balb/c and C57BL/6 mice were obtained from our own
breeding colonies, kept and handled in accordance with
institutional and UK Home Office guidelines. Mouse recombi-
nant GM-CSF and IL-3 were obtained from R&D Systems, Inc.
(Minneapolis, MN). IL-3-conditioned medium was derived by
culture of IL-3-producing WEHI-3 cells in RPMI 1640 (Gibco,
UK) supplemented with 10% heat-inactivated fetal calf serum
(FCS).RAW264.7,b.END-3,NIH3T3andLA-4cells(agiftfrom
Dr. T. Tuthill [44]), were used as models of macrophages,
endothelial cells, fibroblasts and respiratory epithelial cells,
respectively. They were cultured in DMEM supplemented with
10% FCS, 2 mM L-glutamine, penicillin and streptomycin
(b.END-3 cells were also supplemented with 1% w/v non-
essential amino acids, 5 lM 2-mercaptoethanol and 1 mM
sodium pyruvate). Anti-IgE labelled with fluorescein isothio-
cyanate(FITC), anti-CD19 labelled with R-phycoerythrin(PE),
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(Oxford, UK). Anti-CD49b (DX5)-PE and anti-Gr-1-PE were
obtained from BDPharmingen (Franklin Lakes, NJ).Anti-CD3-
FITC was from Caltag Medsystems (Buckingham, UK). Anti-
CD11b-FITC (clone 5C6) [45] and anti-CD11c (clone N418)
[46] were produced in our laboratory. Anti-human-Fc labelled
with allophycocyanin or PE were purchased from Jackson
Immunoresearch Laboratories, Inc.
Generation of GMRa-stable cell lines
RNA was isolated from bone marrow cells of both Balb/c and
C57BL/6 mice according to standard conditions of the
RNAeasy spin protocol (Qiagen). cDNA synthesis was
performed using the Advantage RT-PCR kit (BD Biosciences)
and GMRa was amplified by PCR with the following primers
(Sigma): AGAGGAATTCCACCATGACGTCATCACATGC-
CATG-50 and AGAGGAATTCTAGGGCTGCAGGAGGTCCTT-30.
PCR products were cloned into pCR3.1 vector (Invitrogen Life
Technologies) and sequenced (Sir William Dunn School of
Pathology sequencing service). GMRa isoforms were further
subcloned intotheretroviralvector pFB(neo)(Stratagene)and
transfected into the HEK293T-based Phoenix ecotropic packa-
ging cells using FuGene 6 (Roche). Retroviral supernatants
were collected after 48 h and used to transduce Ba/F3 cells, a
murine IL-3-dependent pro-B cell line. Stable cell lines were
selected and maintained in 0.6 mg/mL geneticin (Sigma-
Aldrich).
Proliferation assay
Ba/F3 cells transduced with either empty vector, the full-
length isoforms (Balb/c or C57BL/6), or the deletion or
truncation isoforms (C57BL/6) of the GMRa were cultured in
RPMI 1640 (Gibco) supplemented with 10% heat-inactivated
FCS and the indicated concentration of cytokines (GM-CSF or
IL-3). Experiments were performed in 96-well plates using an
initial cell density of 1000 cells per well in a final volume of
200 lL with 10% v/v Alamarblue (Serotec). Absorbance was
measured at a wavelength of 570 nm and 600 nm daily during
8 days. Percentage reduction of Alamarblue as a measure of
proliferation was determined according to the manufacturer's
instructions.
Generation of GM-CSF-Fc
GM-CSF was amplified by PCR using the following primers
(Sigma):
GGGGAATTCATGTGGCTGCAGAATTTACTTTTCCT-50 and
GGGGAATTCTTTTTGGCCTGGTTTTTTGCATTCAAA-30. The
PCR product was digested with EcoRI and cloned in the
correct reading frame of a pSecTag2(C) vector (Invitrogen,
UK), which contains the Igj signal peptide and was previously
modified by the insertion of a human IgG1 Fc domain with its
own stop codon [21]. This Fc domain contains four mutations
that remove Fc receptor binding and complement activation
[21]. The resultant vector encoded a GM-CSF-Fc chimeric
protein (referred to as GM-Fc) under the control of the CMV
promoter. GM-Fc was transfected into HEK293T cells using
GeneJuice (Novagen, UK), and stable clones producing GM-Fc
were selected in DMEM (Gibco) containing 4% IgG-depleted
bovine serum and 0.2 mg/mL zeocin (Invitrogen Life Tech-
nologies).
GM-Fc was also subcloned into the BamHI restriction site of
pFB(neo) (Stratagene) subsequent to PCR amplification of
GM-Fc using the following primers: GGAGGATCCACCA-
TGTGGCTGCAGAATTTACTT-50 and GGAGGATCCTCAT-
TTACCCGGAGACAGGG-30. This construct was transfected into
HEK293T-based Phoenix ecotropic packaging cells and the
retrovirus-containing medium was used to transduce NIH3T3
cellsaspreviouslydescribed.Stablecelllineswereselectedand
maintained in DMEM (Gibco) containing 4% IgG-depleted
bovine serum and 0.6 mg/mL geneticin (Sigma-Aldrich).
HEK293T or NIH3T3 cells expressing GM-Fc were left to
condition media (above) for at least 7 days. GM-Fc was
isolated by affinity purification on Protein A-sepharose (GE
Healthcare) and eluted with 0.1 M glycine, pH 2.9. After
neutralisation with 0.1 volume of 1 M Tris, pH 9.5, GM-Fc was
dialysed against PBS and protein concentration determined by
the bicinchoninic acid method (Pierce). The purity of
individual batches of GM-Fc was assessed by Coomassie blue
staining of protein resolved under both reducing and non-
reducing conditions by 10% SDS-PAGE. To establish that
binding of GM-Fc was specific, CR
W117A-Fc was utilized as
control-Fc protein since it contains a mutated version of the
cysteine-rich domain (CR) of the mannose receptor that
abrogates lectin activity and lacks binding capacity [21].
FACS experiments and analysis
The binding of GM-Fc to GMRa-expressing cells (GMRa-
transduced Ba/F3 cells or cells derived from blood, spleen,
bone marrow as well as alveolar and peritoneal lavage) was
determined by FACS. Briefly, cells were incubated in blocking
buffer 1 (PBS containing 5% heat-inactivated rabbit serum,
0.5% BSA, 5 mM EDTA and 2 mM NaN3) for 1 h at 4
 C. GM-Fc
or control-Fc were added at 10 lg/mL in a final volume of
100 lL of washing buffer (PBS containing 0.5% BSA, 5 mM
EDTA and 2 mM NaN3), and incubated for 1 h at 4
 C. After
two washes, cells were incubated with anti-human-allophy-
cocyanin and washed again 1 h later. Cells were incubated in
blocking buffer 2 (PBS containing 5% heat-inactivated rat
serum,0.5%BSA,5 mMEDTA and2 mMNaN3)for1 hat4
 C.
This step was necessary to block residual anti-rat activityof the
anti-human reagent before adding labelled rat anti-mouse
antibodies for the specific markers [IgE, CD19, F4/80, CD49b
(DX5), Gr-1, CD3 and CD11b].
After three washes, cells were resuspended in 1%
formaldehyde (in PBS) and acquired on a FACScalibur (Becton
Dickinson). FACS analysis was performed using FlowJo (Tree
Star, Inc.). Granulocytes were gated on a FSC/SSC plot and
sorted using specific markers: neutrophils (SSC
medCD11b
+
Gr-1
high), eosinophils (SSC
highCD11b
+Gr-1
low) and basophils
(SSC
medCD49b
+IgE
+).Monocytes(SSC
medCD49b
+IgE
+)were
subdividedintoGR-1
+andGr-1
–subsets,andlymphocyteswere
classified as T cells (CD3
+), B cells (CD19
+) and NK cells
(CD3
–CD49b
+).
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RAW264.7 cells were seeded on 24-well plates at a density of
50 000 cells per well in DMEM supplemented with 10% FCS,
L-glutamine, penicillin and streptomycin. Next day, the
medium was removed and cells were cultured in presence of
100 ng/mL of poly(I:C), Pam3CSK4, flagellin, LPS or zymosan
at 5 10
6 particles per well. Cells were incubated at 37
 C for
24 h in presence of the stimuli. After this time, cells were
washed with PBS and incubated with blocking buffer (PBS
containing 5% heat-inactivated rabbit serum, 0.5% BSA and
2m MN a N 3) for 1 h at 4
 C. Cells were stained in situ using
GM-Fc or control-Fc (as described above). After staining, the
cells were lifted with a scraper and transferred to a FACS tube
in 1% formaldehyde. FACS acquisition and analysis were
performedasindicated above.The datafromfour independent
experiments were analysed for statistically significant differ-
ences by one-way repeated measures ANOVA test with
Dunnett's multiple comparison test using GraphPad Prism.
Analysis of the binding of GM-Fc to GMRa isoforms
For analysis of the binding efficiency of GM-Fc to the
polymorphic variants of GMRa, a range of concentrations of
GM-Fc were incubated with GMRa-transduced Ba/F3 cells for
2 h at 4
 C. The cells were washed and the bound protein was
detected as described above using anti-human-allophycocya-
nin and flow cytometry. Specific binding was determined by
subtraction of the non-specific binding of GM-Fc to control
pFBneo-transducedBa/F3cells.Bindingdatawereanalysedby
non-linear regression using GraphPad Prism.
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